Introduction
Material and methods
Patient cohort
n (%) | Overall cohort N = 232 | CT-cohort N = 166 | Non-CT-cohort N = 66 | p-value |
---|---|---|---|---|
Age at diagnosis (years) | ||||
Median (range) | 61 (26–91) | 55.5 (26–76) | 80 (38–91) | < 0.001 |
< 50 | 54 (23.3) | 51 (30.7) | 3 (4.5) | < 0.001 |
50–75 | 131 (56.5) | 114 (68.7) | 17 (25.8) | |
≥ 76 | 47 (20.3) | 1 (0.6) | 46 (69.7) | |
Tumor size | ||||
≤ 20 mm | 113 (48.7) | 83 (50.0) | 30 (45.5) | 0.303 |
> 20 mm | 107 (46.1) | 71 (42.8) | 36 (54.5) | |
Unknown | 12 (5.2) | 12 (7.2) | 0 | |
Lymph node status | ||||
Node negative (N0) | 145 (62.5) | 100 (60.2) | 45 (68.2) | 0.228 |
Node positive (N +) | 86 (37.1) | 66 (39.8) | 20 (30.3) | |
Unknown | 1 (0.4) | 0 | 1 (1.5) | |
Nottingham histologic grade | ||||
1 | 0 | 0 | 0 | 0.004 |
2 | 30 (12.9) | 14 (8.4) | 16 (24.2) | |
3 | 196 (84.5) | 146 (88.0) | 50 (75.8) | |
Unknown | 6 (2.6) | 6 (3.6) | 0 | |
Ki-67 proliferation marker | ||||
≤ 30% | 41 (17.7) | 22 (13.3) | 19 (28.8) | 0.007 |
> 30% | 189 (81.5) | 143 (86.1) | 46 (69.7) | |
Unknown | 2 (0.9) | 1 (0.6) | 1 (1.5) | |
Histological type | ||||
Invasive ductal carcinoma | 183 (78.9) | 132 (79.5) | 51 (77.3) | 0.004 |
Medullary features | 16 (6.9) | 16 (9.6) | 0 | |
Other | 33 (14.2) | 18 (10.8) | 15 (22.7) | |
TIL abundance, % | ||||
Median (range) | 20 (0–100) | 20 (0–90) | 10 (0–100) | 0.028 |
< 30% | 139 (59.9) | 94 (56.6) | 45 (68.2) | 0.100 |
≥ 30% | 91 (39.2) | 71 (42.8) | 20 (30.3) | |
Unknown | 2 (0.9) | 1 (0.6) | 1 (1.5) | |
SP142 IC status | ||||
< 1% | 114 (49.1) | 72 (43.4) | 42 (63.6) | 0.006 |
≥ 1% | 118 (50.9) | 94 (56.6) | 24 (36.4) | |
22C3 CPS status | ||||
< 1 | 107 (43.1) | 68 (41.0) | 39 (59.1) | 0.028 |
≥ 1–9 | 62 (26.7) | 51 (30.7) | 11 (16.7) | |
≥ 10 | 63 (27.2) | 47 (28.3) | 16 (24.2) | |
22C3 IC status | ||||
< 1% | 135 (58.2) | 91 (54.8) | 44 (66.7) | 0.107 |
≥ 1% | 97 (41.8) | 75 (45.2) | 22 (33.3) | |
Follow-up time | ||||
Median, months (range) | 68 (5–108) | 70 (5–108) | 64 (6–106) | 0.014 |
< 2 y | 20 (8.6) | 9 (5.4) | 11 (16.7) | 0.009 |
2–5 y | 51 (22.0) | 35 (21.1) | 16 (24.2) | |
> 5 y | 159 (68.5) | 122 (73.5) | 37 (56.1) | |
Unknown | 2 (0.9) | 0 | 2 | |
Events, yes event occured | ||||
Death (OS event) | 54 (23.3) | 33 (19.9) | 21 (31.8) | 0.059 |
Relapse (distant or locoregional) | 49 (21.1) | 34 (20.5) | 15 (22.7) | 0.720 |
Relapse or death (IDFS event) | 69 (29.7) | 42 (25.3) | 27 (40.9) | 0.026 |
Distant relapse (DRFI event) | 39 (16.8) | 28 (16.9) | 11 (16.7) | 1.000 |
PD-L1 immunohistochemistry (IHC) and tissue microarray (TMA)
PD-L1 IHC scoring
Evaluation of tumor infiltrating lymphocytes (TILs)
Clinical endpoints
Statistical analyses and analyses of RNA sequencing data
Results
Frequency of PD-L1 IHC expression
Comparison between SP142 and 22C3
Association of SP142 and 22C3 with PD-L1 (CD274) gene expression (mRNA)
Clinicopathological features in the CT-cohort and the non-CT-cohort
Association of PD-L1 status with clinicopathological features
n (%) | SP142 IC 1% cut-off | 22C3 CPS 10 cut-off | ||||
---|---|---|---|---|---|---|
IC < 1% N = 72 (43.4%) | IC ≥ 1% N = 94 (56.6%) | p-value | CPS < 10 N = 119 (71.7%) | CPS ≥ 10 N = 47 (28.3%) | p-value | |
Age at diagnosis, years | ||||||
Median (range) | 58 (26–74) | 54 (28–76) | 0.237 | 56 (26–76) | 54 (31–75) | 0.851 |
< 50 y | 21 (29.2) | 30 (31.9) | 0.737 | 36 (30.3) | 15 (31.9) | 0.853 |
≥ 50 y | 51 (70.8) | 64 (68.1) | 83 (69.7) | 32 (68.1) | ||
Tumor size | ||||||
≤ 20 mm | 32 (44.4) | 51 (54.3) | 0.869 | 54 (45.4) | 29 (61.7) | 0.222 |
> 20 mm | 29 (40.3) | 42 (44.7) | 53 (44.5) | 18 (38.3) | ||
Unknown | 11 (15.3) | 1 (1.1) | 12 (10.1) | 0 | ||
Lymph node status | ||||||
N0 | 40 (55.6) | 58 (61.7) | 0.749 | 71 (59.7) | 29 (61.7) | 0.862 |
N + | 32 (44.4) | 36 (38.3) | 48 (40.3) | 18 (38.3) | ||
Histologic grade | ||||||
1 | 0 | 0 | 0 | 0 | ||
2 | 11 (15.3) | 3 (3.2) | 0.004 | 13 (10.9) | 1 (2.1) | 0.067 |
3 | 55 (76.4) | 91 (96.8) | 100 (84.0) | 46 (97.9) | ||
Unknown | 6 (8.3) | 0 | 6 (5.0) | 0 | ||
Ki-67 | ||||||
≤ 30% | 16 (22.2) | 6 (6.4) | 0.005 | 18 (15.1) | 4 (8.5) | 0.316 |
> 30% | 55 (76.4) | 88 (93.6) | 100 (84.0) | 43 (91.5) | ||
Unknown | 1 (1.4) | 0 | 1 (0.8) | 0 | ||
Histological type | ||||||
Invasive ductal carcinoma | 59 (81.9) | 73 (77.7) | 0.001 | 98 (82.4) | 34 (72.3) | < 0.001 |
Medullary features | 1 (1.4) | 15 (16.0) | 5 (4.2) | 11 (23.4) | ||
Other | 12 (16.7) | 6 (6.4) | 16 (13.4) | 2 (4.3) | ||
TIL abundance | ||||||
Median, % (range) | 10 (0–60) | 40 (1–90) | < 0.001 | 15 (0–80) | 50 (5–90) | < 0.001 |
< 30% | 58 (80.6) | 36 (38.3) | < 0.001 | 84 (70.6) | 10 (21.3) | < 0.001 |
≥ 30% | 14 (19.4) | 57 (60.6) | 34 (28.6) | 37 (78.7) | ||
Unknown | 0 | 1 (1.1) | 1 (0.8) | 0 |
Association of PD-L1 with patient outcome in the CT-cohort
IDFS univariable (events = 42) | IDFS multivariable (events = 37) | OS univariable (events = 33) | OS multivariable (events = 29) | DRFI univariable (events = 28) | DRFI multivariable (events = 23) | |||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|
HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | HR (95% CI) | p | |
(A) | ||||||||||||
Age | 1.22 (0.61–2.42) | 0.572 | 0.86 (0.39–1.92) | 0.716 | 1.60 (0.70–3.70) | 0.268 | 1.65 (0.60–4.49) | 0.330 | 0.92 (0.42–2.04) | 0.845 | 0.77 (0.30–1.98) | 0.593 |
Tumor size | 0.84 (0.43–1.61) | 0.596 | 0.59 (0.29–1.21) | 0.151 | 1.35 (0.65–2.79) | 0.425 | 1.17 (0.54–2.55) | 0.690 | 1.36 (0.60–3.08) | 0.463 | 0.93 (0.39–2.25) | 0.878 |
Lymph nodes | 1.58 (0.86–2.90) | 0.138 | 1.73 (0.86–3.49) | 0.127 | 1.51 (0.76–2.99) | 0.236 | 1.29 (0.59–2.82) | 0.518 | 2.34 (1.11–4.95) | 0.026 | 2.00 (0.84–4.80) | 0.118 |
Histologic grade | 0.68 (0.27–1.75) | 0.427 | 1.01 (0.37–2.72) | 0.992 | 0.51 (0.21–1.70) | 0.330 | 0.91 (0.30–2.74) | 0.863 | 1.09 (0.26–4.62) | 0.909 | 1.29 (0.29–5.83) | 0.739 |
TIL abundance | 0.38 (0.19–0.78) | 0.008 | 0.27 (0.11–0.67) | 0.005 | 0.47 (0.22–1.01) | 0.053 | 0.49 (0.19–1.28) | 0.146 | 0.50 (0.22–1.13) | 0.095 | 0.33 (0.11–0.99) | 0.047 |
SP142 IC < 1% versus ≥ 1% | 0.48 (0.26–0.89) | 0.020 | 0.76 (.38–1.54) | 0.450 | 0.53 (0.26–1.05) | 0.069 | 0.78 (0.35–1.75) | 0.544 | 0.47 (0.22–1.00) | 0.049 | 0.80 (0.33–1.93) | 0.612 |
(B) | ||||||||||||
Age | 0.84 (0.38–1.87) | 0.675 | 1.61 (0.59–4.38) | 0.348 | 0.78 (0.31–2.00) | 0.610 | ||||||
Tumor size | 0.60 (0.30–1.21) | 0.155 | 1.16 (0.53–2.53) | 0.704 | 0.91 (0.38–2.19) | 0.840 | ||||||
Lymph nodes | 1.69 (0.84–3.39) | 0.139 | 1.28 (0.59–2.80) | 0.531 | 2.11 (0.89–5.01) | 0.090 | ||||||
Histologic grade | 0.95 (0.36–2.54) | 0.920 | 0.87 (0.29–2.60) | 0.805 | 1.39 (0.31–6.16) | 0.664 | ||||||
TIL abundance | 0.27 (0.11–0.68) | 0.006 | 0.48 (0.18–1.30) | 0.147 | 0.47 (0.16–1.39) | 0.173 | ||||||
22C3 CPS < 10 versus ≥ 10 | 0.46 (0.21–1.04) | 0.061 | 0.82 (0.33–2.04) | 0.666 | 0.51 (0.21–1.24) | 0.137 | 0.83 (0.30–2.34) | 0.728 | 0.18 (0.04–0.76) | 0.019 | 0.26 (0.06–1.20) | 0.084 |
(C) | ||||||||||||
Age | 0.84 (0.38–1.88) | 0.677 | 1.63 (0.60–4.42) | 0.342 | 0.77 (0.30–1.97) | 0.588 | ||||||
Tumor size | 0.61 (0.30–1.23) | 0.167 | 1.19 (0.55–2.60) | 0.658 | 0.96 (0.40–2.30) | 0.926 | ||||||
Lymph nodes | 1.67 (0.83–3.33) | 0.149 | 1.27 (0.58–2.74) | 0.550 | 1.95 (0.82–4.62) | 0.131 | ||||||
Histologic grade | 0.97 (0.36–2.63) | 0.949 | 0.90 (0.30–2.74) | 0.859 | 1.39 (0.31–6.27) | 0.668 | ||||||
TIL abundance | 0.27 (0.10–0.70) | 0.007 | 0.51 (0.18–1.42) | 0.198 | 0.41 (0.12–1.34) | 0.138 | ||||||
22C3 CPS < 1 versus ≥ 1 | 0.53 (0.29–0.98) | 0.043 | 0.86 (0.40–1.81) | 0.684 | 0.56 (0.28–1.10) | 0.093 | 0.79 (0.33–1.90) | 0.595 | 0.49 (0.23–1.04) | 0.063 | 0.59 (0.22–1.57) | 0.293 |
(D) | ||||||||||||
Age | 0.84 (0.38–1.86) | 0.658 | 1.61 (0.59–4.37) | 0.359 | 0.77 (0.30–1.97) | 0.588 | ||||||
Tumor size | 0.60 (0.30–1.22) | 0.159 | 1.17 (0.54–2.60) | 0.688 | 0.96 (0.40–2.31) | 0.924 | ||||||
Lymph nodes | 1.67 (0.83–3.33) | 0.150 | 1.26 (0.58–2.74) | 0.558 | 1.97 (0.83–4.70) | 0.125 | ||||||
Histologic grade | 0.92 (0.34–2.45) | 0.861 | 0.85 (0.29–2.54) | 0.773 | 1.28 (0.29–5.70) | 0.748 | ||||||
TIL abundance | 0.24 (0.09–0.63) | 0.003 | 0.44 (0.16–1.22) | 0.116 | 0.37 (0.11–1.16) | 0.088 | ||||||
22C3 IC < 1% versus ≥ 1% | 0.57 (0.30–1.08) | 0.086 | 1.03 (0.48–2.21) | 0.936 | 0.66 (0.33–1.35) | 0.256 | 1.00 (0.42–2.38) | 0.992 | 0.47 (0.21–1.06) | 0.068 | 0.70 (0.26–1.91) | 0.488 |